Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Moodys
AstraZeneca
McKesson
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,667,314

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,667,314 protect, and when does it expire?

Patent 6,667,314 protects SELZENTRY and is included in two NDAs.

This patent has ninety-six patent family members in fifty-five countries.

Summary for Patent: 6,667,314
Title: Tropane derivatives useful in therapy
Abstract:The present invention provides compounds of the formula: ##STR1## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
Inventor(s): Perros; Manoussos (County of Kent, GB), Price; David Anthony (County of Kent, GB), Stammen; Blanda Luzia Christa (County of Kent, GB), Wood; Anthony (County of Kent, GB)
Assignee: Pfizer, Inc. (New York, NY)
Application Number:09/865,950
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,667,314

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1   Start Trial
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No   Start Trial   Start Trial Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1   Start Trial
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No   Start Trial   Start Trial Y Y METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,667,314

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0015835Jun 27, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Merck
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.